[
    {
        "id": "osp-12346",
        "type": "article-journal",
        "title": "Chronic myelogenous leukemia in a child following treatment for bilateral retinoblastoma",
        "author": [
            {
                "family": "Al-Mahrouqi",
                "given": "Haitham Hilal"
            },
            {
                "family": "Ganesh",
                "given": "Anuradha"
            },
            {
                "family": "Al-Rawas",
                "given": "Abdul Hakim"
            },
            {
                "family": "Khetan",
                "given": "Vikas"
            },
            {
                "family": "Al-Zuhaibi",
                "given": "Sana"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/chronic-myelogenous-leukemia-in-a-child-following-treatment-for-bilateral-retinoblastoma",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2021
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "14",
        "issue": "3",
        "page": "187-189",
        "DOI": "10.4103/ojo.ojo_107_21",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "A 3-year-old child was incidentally found to have chronic myelogenous leukemia (CML) during an admission for a routine ophthalmic examination under anesthesia. The child had received systemic chemotherapy and focal treatment for Groups C and D retinoblastoma in the right and left eye, respectively, when she was 7 months old. CML was treated with dasatinib, and the child attained a major molecular response. The child is now 3 years after treatment of CML, and the retinoblastoma remains inactive. CML following treatment of retinoblastoma is a rare occurrence. Long term and close monitoring of retinoblastoma patients who received systemic chemotherapy using serial blood tests is essential."
    }
]